Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

Human Gene Therapy

Volumn 10, Issue 3, 1999, Pages 385-393

  Toda, Masahiro ^a,b   Rabkin, Samuel D ^a   Kojima, Hidefumi ^c   Martuza, Robert L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b KEIO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; HERPES SIMPLEX VIRUS 1; MELANOMA CELL; MOUSE; NONHUMAN; TUMOR IMMUNITY; TUMOR MODEL; VIRUS INFECTION;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; CANCER VACCINES; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, INTRALESIONAL; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; SIMPLEXVIRUS; TIME FACTORS; VIRAL VACCINES;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0033540654     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018832     Document Type: Article

References (38)

1. ANDREANSKY, S.S., HE, B., GILLESPIE, G.Y., SOROCEANU, L., MARKERT, J., CHOU, J., ROIZMAN, B., and WHITLEY, R.J. (1996). The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. U.S.A. 93, 11313-11318.
2. BOON, T., CEROTTINI, J.-C., VAN DEN EYNDE, B., VAN DER BRUGGEN, P., and VAN PEL, A. (1994). Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365.
3. BOVIATSIS, E.J., PARK, J.S., SENA-ESTEVES, M., KRAMM, C.M., CHASE, M., EFIRD, J.T., WEI, M.X., BREAKFIELD, X.O., and CHIOCCA, E.A. (1994). Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54, 5745-5751.
4. BRATTAIN, M.G., STROBEL-STEVENS, J., FINE, D., WEBB, M., and SARRIF, A.M. (1980). Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 40, 2142-2145.
5. DIALYNAS, D.P., WILDE, D.B., MARRACK, P., PIERRES, A., WALL, K.A., HAVRAN, W., OTTEN, G., LOKEN, M.R., PIERRES, M., KAPPLER, J., and FITCH, F.W. (1983). Characterization of the murine antigenic determinant designated L3T4a recognized by monoclonal antibody GK1.5: Expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol. Rev. 74, 29-56.
6. DRANOFF, G., and MULLIGAN, R.C. (1995). Gene transfer as cancer therapy. Adv. Immunol. 58, 417-454.
7. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
8. FEARON, E.R., ITAYA, T., HUNT, B., VOGELSTEIN, B., and FROST, P. (1988). Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 35, 2975-2980.
9. GLIMCHER, L.H., KIM, K.J., GREEN, I., and PAUL, W.E. (1982). Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J. Exp. Med. 155, 445-459.
10. HUANG, A.Y.C., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D., and LEVITSKY, H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
11. HUANG, A.Y.C., GULDEN, P.H., WOODS, A.S., THOMAS, M.C., TONG, C.D., WANG, W., ENGELHARD, V.H., PASTERNACK, G., COTTER, R., HUNT, D., PARDOLL, D.M., and JAFFEE, E.M. (1996). The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. U.S.A. 93, 9730-9735.
12. HUNTER, W., RABKIN, S., and MARTUZA, R. (1995). Brain tumor therapy using genetically engineered replication-competent virus. In Viral Vectors. M.G. Kaplitt and A. D. Loewy, eds. (Academic Press, San Diego, CA) pp. 259-274.
13. JIA, W.W., McDERMOTT, M., GOLDIE, J., CYANDER, M., TAN, J., and TUFARO, F. (1994). Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J. Natl. Cancer Inst. 86, 1209-1215.
14. KAPLITT, M.G., TJUVAJEV, J.G., LEIB, D.A., BERK, J., PETTIGREW, K.D., POSNER, J.B., PFAFF, D.W., RABKIN, S.D., and BLASBERG, R.G. (1994). Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J. Neuro-Oncol. 19, 137-147.
15. KESARI, S., RANDAZZO, B.P., VALYI-NAGY, T., HUANG, Q.S., BROWN, S.M., MACLEAN, A.R., LEE, V., TROJANOWSKI, J.Q., and FRASER, N.W. (1995). Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. 73, 636-648.
16. KIM, K.J., KANELLOPOULOS-LANGEVIN, C., MERWIN, R.M., SACHS, D.H., and ASOFSKY, R. (1979). Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122, 549-554.
17. KOJIMA, H., SHINOHARA, N., HANAOKA, S., SOMEYA-SHIROTA, Y., TAKAGAKI, Y., OHNO, H., SAITO, T., KATAYAMA, T., YAGITA, H., OKUMURA, K., SHINKAI, Y., ALT, F.W., MATSUZAWA, A., YONEHARA, S., and TAKAYAMA, H. (1994). Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1, 357-364.
18. KUCHARCZUK, J.C., RANDAZZO, B., CHANG, M.Y., AMIN, K.M., ELSHAMI, A.A., STERMAN, D.H., RIZK, N.P., MOLNAR-KIMBER, K.L., BROWN, S.M., MACLEAN, A.R., LITZKY, L.A., FRASER, N.W., ALBELDA, S.M., and KAISER, L.R. (1997). Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res. 57, 466-471.
19. LASNER, T.M., KESARI, S., BROWN, S.M., LEE, V.M.Y., FRASER, N.W., and TROJANOWSKI, J.Q. (1996). Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J. Neuropathol. Exp. Neurol. 55, 1259-1269.
20. LEO, O., FOO, M., SEGAL, D., SHEVACK, E., and BLUESTONE, J.A. (1987). Activation of murine T lymphocytes with monoclonal antibodies: Detection of Lyt-2+ cells of an antigen not associated with the T cell receptor complex but involved in T cell activation. J. Immunol. 139, 1214-1222.
21. MARTUZA, R.L., MALICK, A., MARKERT, J.M., RUFFNER, K.L., and COEN, D.M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
22. MINETA, T., RABKIN, S.D., and MARTUZA, R.L. (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963-3966.
23. MINETA, T., RABKIN, S.D., YAZAKI, T., HUNTER, W.D., and MARTUZA, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1, 938-943.
24. MUELLER, D.L., JENKINS, M.K., and SCHWARTZ, R.H. (1989). Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7, 445-480.
25. PARK, S.Y., KOJIMA, M., SUZUKI, H., and SHINOHARA, N. (1992). Effective blocking of natural cytotoxicity of young rabbit serum on murine thymocytes by high concentration of glucose in complement-dependent cytotoxicity method. J. Immunol. Methods 154, 109-119.
26. PLAUTZ, G.E., YANG, Z.-Y., WU, B.-Y., GAO, X., HUANG, L., and NABEL, G.J. (1993). Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. U.S.A. 90, 4645-4649.
27. PYLES, R.B., WARNICK, R.E., CHALK, C.L., SZANTI, B.E., and PARYSEK, L.M. (1997). A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8, 533-544.
28. RANDAZZO, B.P., KESARI, S., GESSER, R.M., ALSOP, D., FORD, J.C., BROWN, S.M., MACLEAN, A., and FRASER, N.W. (1995). Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211, 94-101.
29. RANDAZZO, B.P., BHAT, M.G., KESARI, S., FRASER, N.W., and BROWN, S.M. (1997). Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J. Invest. Dermatol. 108, 933-937.
30. ROCK, K.L., ROTHSTEIN, L., GAMBLE, S., and FLIESCHACKER, C. (1993). Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J. Immunol. 150, 438-446.
31. ROTH, C., ROCHLITZ, C., and KOURILSKY, P. (1994). Immune response against tumors. Adv. Immunol. 57, 281-351.
32. SCHMIDT, W., STEINLEIN, P., BUSCHLE, M., SCHWEIGHOFFER, T., HERBST, E., MECHTLER, K., KIRLAPPOS, H., and BIRNSTIEL, M.L. (1996). Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines. Proc. Natl. Acad. Sci. U.S.A. 93, 9759-9763.
33. SINKOVICS, J., and HORVATH, J. (1993). New developments in the virus therapy of cancer: A historical review. Intervirology 36, 193-214.
34. TODA, M., MARTUZA, R.L., KOJIMA, H., and RABKIN, S.D. (1998a). In situ cancer vaccination: An IL-12 detective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457-4464.
35. TODA, M., RABKIN, S.D., and MARTUZA, R.L. (1998b). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther. 9, 2177-2185.
36. VAN DEN EYNDE, B., LETHE, B., VAN PEL, B., DE PLAEN, E., and BOON, T. (1991). The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173, 1373-1384.
37. WANG, M., BRONTE, V., CHEN, P.W., GRITZ, L., PANICALI, D., ROSENBERG, S.A., and RESTIFO, N.P. (1995). Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154, 4685-4692.
38. ZATLOUKAL, K., SCHNEEBERGER, A., BERGER, M., SCHMIDT, W., KOSZIK, F., KUTIL, R., COTTEN, M., WAGNER, E., BUSCHLE, M., and MAASS, G., (1995). Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J. Immunol. 19, 3406-3419.